IN THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claims 1-7 (canceled).

Claim 8 (previously presented): An effervescent pharmaceutical composition comprising levodopa methyl ester and an acid-base couple, wherein administering a single oral dose of said composition to a human provides to said human a maximum plasma concentration of levodopa at about 0.3 hours (T_{max}) after said administering.

Claim 9 (previously presented): The composition of claim 8, wherein said acid-base couple is sodium glycine carbonate-fumaric acid.

Claim 10 (previously presented): The composition of claim 9, wherein said composition further comprises carbidopa monohydrate.

Claim 11 (previously presented): The composition of claim 10, wherein the weight ratio of levodopa methyl ester to carbidopa monohydrate to sodium glycine carbonate to fumaric acid is about 1.0:0.09:1.7:1.1, respectively.

Claim 12 (previously presented): A pharmaceutical composition comprising levodopa methyl ester (LDME) and an acid-base couple, wherein administering a single oral dose of said composition to a human provides to said human a mean maximum plasma

concentration of levodopa (C_{max}/dose) of about 9.6 ng/mL/[mg LDME] after said administering.

Claim 13 (previously presented): The composition of claim 12, wherein said acid-base couple is sodium glycine carbonate-fumaric acid.

Claim 14 (previously presented): The composition of claim 13, wherein said composition further comprises carbidopa monohydrate.

Claim 15 (previously presented): The composition of claim 14, wherein the weight ratio of levodopa methyl ester to carbidopa monohydrate to sodium glycine carbonate to fumaric acid is about 1.0:0.09:1.7:1.1, respectively.

Claim 16 (previously presented): The composition of claim 12, wherein said C_{max} is about 3000 [± 1592] ng/mL when said single oral dose contains 314 mg of LDME.

Claim 17 (previously presented): A pharmaceutical composition comprising levodopa methyl ester (LDME) and an acid-base couple, wherein administering a single oral dose of said composition to a human provides to said human an area under the curve of levodopa in plasma from 0 to 1 hour (AUC_{1h}/dose) of about 5.3 ng·hr/mL/[mg LDME] after said administering.

Claim 18 (previously presented): The composition of claim 17, wherein said AUC_{1h} is about 1683 [± 1074] ng·hr/mL when said single oral dose contains 314 mg of LDME.

Claim 19 (previously presented): The composition of claim 17, wherein said acid-base couple is sodium glycine carbonate-fumaric acid.

Claim 20 (previously presented): The composition of claim 17, wherein said composition further comprises carbidopa monohydrate.

Claim 21 (previously presented): The composition of claim 20, wherein the weight ratio of levodopa methyl ester to carbidopa monohydrate to sodium glycine carbonate to fumaric acid is about 1.0:0.09:1.7:1.1, respectively.

Claim 22 (previously presented): A pharmaceutical composition comprising levodopa methyl ester and an acid-base couple, wherein administering a single oral dose of said composition to a human provides to said human a ratio of about 2.7 of mean plasma concentration of levodopa at 15 minutes after said administering compared to 60 minutes after said administering.

Claim 23 (previously presented): The composition of claim 22, wherein said acid-base couple is sodium glycine carbonate-fumaric acid.

Claim 24 (previously presented): The composition of claim 23, wherein said composition further comprises carbidopa monohydrate.

Claim 25 (previously presented): The composition of claim 24, wherein the weight ratio of levodopa methyl ester to carbidopa monohydrate to sodium glycine carbonate to fumaric acid is about 1.0:0.09:1.7:1.1, respectively.

Claim 26 (previously presented): A pharmaceutical composition comprising levodopa methyl ester (LDME) and an acid-base couple, wherein administering a single oral dose of said composition to a human provides to said human a mean plasma concentration (C_p) of levodopa of about 8.8 ng/mL/[mg LDME] 15 minutes after said administering.

Claim 27 (previously presented): The composition of claim 26, wherein said C_p is about 2787 ng/mL 15 minutes after said administering when said single oral dose contains 314 mg of LDME.

Claim 28 (previously presented): The composition of claim 26, wherein said administering further provides to said human a mean plasma concentration of levodopa of about 5.4 ng/mL/[mg LDME] 30 minutes after said administering.

Claim 29 (previously presented): The composition of claim 28, wherein said C_p is about 1705 ng/mL 30 minutes after said administering when said single oral dose contains 314 mg of LDME.

Claim 30 (previously presented): The composition of claim 28, wherein said administering further provides to said human a mean plasma concentration of levodopa of about 4.2 ng/mL/[mg LDME] 45 minutes after said administering.

Claim 31 (previously presented): The composition of claim 30, wherein said C_p is about 1339 ng/mL 45 minutes after said administering when said single oral dose contains 314 mg of LDME.

Claim 32 (previously presented): The composition of claim 26, wherein said acid-base couple is sodium glycine carbonate-fumaric acid.

Claim 33 (previously presented): The composition of claim 32, wherein said composition further comprises carbidopa monohydrate.

Claim 34 (previously presented): The composition of claim 33, wherein the weight ratio of levodopa methyl ester to carbidopa monohydrate to sodium glycine carbonate to fumaric acid is about 1.0:0.09:1.7:1.1, respectively.

Claim 35 (withdrawn): A method of providing levodopa to a human in need thereof, said method comprising orally administering to said human an effervescent composition comprising levodopa methyl ester and an acid-base couple, wherein a single oral dose of said composition provides to said human a maximum plasma concentration of levodopa (T_{max}) at about 0.3 hours after said administering.

Claim 36 (withdrawn): The method of claim 35, wherein said acid-base couple is sodium glycine carbonate-fumaric acid.

Claim 37 (withdrawn): The method of claim 36, wherein said composition further comprises carbidopa monohydrate.

Claim 38 (withdrawn): The method of claim 37, wherein the weight ratio of levodopa methyl ester to carbidopa monohydrate to sodium glycine carbonate to fumaric acid is about 1.0:0.09:1.7:1.1, respectively.

Claim 39 (withdrawn): A method of providing levodopa to a human in need thereof, said method comprising orally administering to said human a composition comprising levodopa methyl ester (LDME) and an acid-base couple, wherein a single oral dose of said composition provides to said human a mean maximum plasma concentration of levodopa (C_{max}/dose) of about 9.6 ng/mL/[mg LDME] after said administering.

Claim 40 (withdrawn): The method of claim 39, wherein said C_{max} is about 3000 [± 1592] ng/mL when said single oral dose contains 314 mg of LDME.

Claim 41 (withdrawn): The method of claim 39, wherein said acid-base couple is sodium glycine carbonate-fumaric acid.

Claim 42 (withdrawn): The method of claim 41, wherein said composition further comprises carbidopa monohydrate.

Claim 43 (withdrawn): The method of claim 42, wherein the weight ratio of levodopa methyl ester to carbidopa monohydrate to sodium glycine carbonate to fumaric acid is about 1.0:0.09:1.7:1.1, respectively.

Claim 44 (withdrawn): A method of providing levodopa to a human in need thereof, said method comprising orally administering to said human a composition comprising levodopa methyl ester (LDME) and an acid-base couple, wherein a single oral dose of said composition provides to said human an area under the curve of levodopa in plasma from 0 to 1 hour (AUC_{1h}/dose) of about 5.3 ng·hr/mL/[mg LDME] after said administering.

Claim 45 (withdrawn): The method of claim 44, wherein said AUC_{1h} is about 1683 [± 1074] ng·hr/mL when said single oral dose contains 314 mg of LDME.

Claim 46 (withdrawn): The method of claim 44, wherein said acid-base couple is sodium glycine carbonate-fumaric acid.

Claim 47 (withdrawn): The method of claim 46, wherein said composition further comprises carbidopa.

Claim 48 (withdrawn): The method of claim 47, wherein the weight ratio of levodopa methyl ester to carbidopa monohydrate to sodium glycine carbonate to fumaric acid is about 1.0:0.09:1.7:1.1, respectively.

Claims 49-53 (canceled).

Claim 54 (previously presented): The composition of claim 12, wherein said acid-base couple is sodium glycine carbonate-fumaric acid and which further comprises carbidopa monohydrate,

wherein the weight ratio of levodopa methyl ester to carbidopa monohydrate to sodium glycine carbonate to fumaric acid is about 1.0:0.09:1.7:1.1, respectively, and

wherein said C_{max} is about 3000 [± 1592] ng/mL when said single oral dose contains 314 mg of LDME.

Claim 55 (previously presented): The composition of claim 17, wherein said AUC_{1h} is about 1683 [± 1074] ng·hr/mL when said single oral dose contains 314 mg of LDME,

wherein said acid-base couple is sodium glycine carbonate-fumaric acid,

wherein said composition further comprises carbidopa monohydrate, and

wherein the weight ratio of levodopa methyl ester to carbidopa monohydrate to sodium glycine carbonate to fumaric acid is about 1.0:0.09:1.7:1.1, respectively.

Claim 56 (new): The composition of claim 8, which is not coated with an enteric coating.

Claim 57 (new): The composition of claim 12, which is not coated with an enteric coating.

Claim 58 (new): The composition of claim 17, which is not coated with an enteric coating.

Claim 59 (new): The composition of claim 22, which is not coated with an enteric coating.

Claim 60 (new): The composition of claim 26, which is not coated with an enteric coating.